4D Molecular Therapeutics shares are trading higher after the company completed enrollment for its 4FRONT-2 second Phase 3 trial for 4D-150 to treat macular degeneration. The company also secured a $200 million strategic credit facility from Hercu...

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc.

FDMT

0.00
4D Molecular Therapeutics shares are trading higher after the company completed enrollment for its 4FRONT-2 second Phase 3 trial for 4D-150 to treat macular degeneration. The company also secured a $200 million strategic credit facility from Hercules Capital.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.